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ABSTRACT
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?nity analog of GTP with the proteins of microtu

diagnose a neurological disease. For instance, Alzhei
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4375-4377.

mer’s disease can be diagnosed by detecting a disease

Gurney, M. E. Nature 307(5951): 546-548 (1984).
Norenberg, M. D. J. Histochem. & Cytochem.

27(3):756—762 (1979).

speci?c protein having a molecular weight of about

42,000 daltons, i.e., glutamine synthetase.
15 Claims, No Drawings

_

1

5,272,055

DETECTION OF ALZHEIMER’S DISEASE AND
OTHER DISEASES USING A PHOTOAFFINITY
LABELING METHOD

sections.

It is problematic, however, that histochemical stain
ing is not always reproducible, neuritic plaques and
neuro?brillary tangles are not uniformly distributed,

FIELD OF THE INVENTION
The present invention relates to novel compositions,
methods and test kits which use the procedure of pho

and histopathologic studies are time-consuming and
labor-intensive. Moreover, there is no direct evidence
that an accumulation of abnormal cytoskeletal ?brils
contributes directly to premature dysfunction and death
of the neurons; rather, the ?brils may simply be a mani
festation of more fundamental cellular changes. The
clinical and pathologic progression of Alzheimer’s dis

toaf?nity labeling with nucleotide affinity probes, to
detect neurological disease using cerebral spinal ?uid,
blood, tissue, or other specimens in a mammal. The

present invention provides a method of diagnosis based
on a disease-speci?c biochemical marker macromole
cule which, if present, can be identi?ed in a small bio

logical sample from ya patient. In particular, the present

case is marked by a continuing loss of neurons from the

invention concerns a method for diagnosing Alzhei

cerebral cortex. However, neuritic plaques and neuro?
brillary tangles may occur in nondemented elderly pa

mer’s disease using a disease-speci?c nucleotide binding
protein and detecting the binding of that protein in the
cerebral spinal ?uid of a patient af?icted with Alzhei
mer’s disease.

2

neurohistopathologic identi?cation and counting of
neuritic plaques and neuro?brillary tangles requires
staining and microscopic examination of several brain

tients, as well as those afflicted with Alzheimer’s dis
20

BACKGROUND OF THE INVENTION

Alzheimer’s disease (AD) is an idiopathic progressive
dementia that will affect a large percentage of our aging

ease.

Current research to develop both an understanding of
the disease and a possible diagnostic test has centered on

the amyloid protein and its precursor protein. Theoreti
cally, diagnosis has been based on the deposition of

population. To date its etiology is still unknown. The 25 amyloid containing plaques in the cortical region in the
brain of individuals affected with Alzheimer’s disease.
neurodegenerative disease is characterized by a chroni
Such diagnostic methods have been disclosed in, for
cally deteriorating course of impaired intellectual func
example,
U.S. Pat. No. 4,666,829, 4,701,407, 4,816,416
tion and memory loss.
and 4,933,156.
Relatively little is known of the pathophysiological
However, amyloid deposits are also found in the
chain of events that leads to the premature dysfunction
brains of aged individuals who have never displayed
and death of affected neurons in Alzheimer’s disease
signs of dementia. For example, a recent article (J. Biol.
patients. Multiple abnormalities have been reported in
Chem., 265:15977 (1990)) has shown that there were no
the brains of patients who have been diagnosed as hav
differences in the primary structure of precursor amy
ing Alzheimer’s disease, but it is difficult to determine
which of these are the result of brain damage and which 35 loid protein from platelets of normal individuals and
that of Alzheimer’s disease patients. Therefore, while
contribute to premature neuronal dysfunction and
amyloid protein may be involved in Alzheimer’s dis
death.
ease, other methods have been pursued to identify char
At the present time, the clinical diagnosis of Alzhei
acteristics more uniquely related to a patient with Alz
mer’s disease is one of exclusion. Secondary causes of
loss of memory and impaired cognitive function may 40 heimer’s disease. For instance, U.S. Pat. No. 4,727,041,
issued to Aroonsakul, discloses a comparative test for
result from multiple infarcts, leading to so-called multi
infarct dementia, or from intracranial mass lesions, such
as subdural hematomas, brain tumors, or granulomas.
Central nervous system infections of viral and bacterial
origin, or even slow viral disorders such as Creutzfeldt 45

the diagnosis of Alzehimer’s disease in humans by deter
mining levels of somatotropin and somatomedin-C in
the patient’s blood sera drawn at intervals following
administration of an L-dopa provocative test.

Jakob disease. are part of the differential diagnosis.

Immunoassay methods have also been developed for

Furthermore, metabolic disorders involving vitamin
B12 metabolism, thiamine or folate de?ciency, thyroid
dysfunction, hepatic and renal failure, as well as drug

detecting the presence of neurochemical markers in
Alzheimer’s disease patients. U.S. Pat. Nos. 4,728,605
and 4,801,533, issued to Fudenberg et al., disclose com

toxicity may appear as dementia. Nevertheless, when all 50 parative methods for diagnosing degenerative disease of
these secondary ‘causes, many of which are reversible,
the central nervous system, particularly Alzheimer’s
are eliminated, cerebral atrophy of unknown cause or

disease, by measuring immunological parameters and

Alzheimer’s disease still covers the largest number of

interactive T cells from a patient’s peripheral blood.
U.S. Pat. No. 4,806,627, issued to Wisniewski et al.,

patients.

The de?nitive diagnosis of Alzheimer’s disease is 55 discloses protease resistant proteins which comprise
made by pathologic examination of postmortem brain
scrapie-associated ?brils and a scrapie-speci?c mono
tissue in conjunction with a clinical history of dementia.
clonal antibody to distinguish certain neurological dis
This diagnosis is based on the presence in brain tissue of
ease-caused human dementias from Alzheimer’s disease.
intraneuronal neuro?brillary tangles and of neuritic
However, none of the known methods of diagnosis
(senile) plaques, which have been correlated with clini 60 have proven to be a reliable means of detection of A12
cal dementia. Although the cause of the abnormal cy
heimer’s disease in all patients, particularly at early
toskeletal ?brils remains unknown, neuritic plaques are
stages of the disease. As a result, alternative methods of
thought to be composed of degenerating axons and
diagnosis have been proposed which rely on analyzing
nerve terminals as well as possible astrocytic elements,
the cerebral spinal ?uid drawn from the affected pa
and they often exhibit a central amyloid protein core.
tients. For example, Warner in Anal. Chem,
The neuro?brillary tangles are interneuronal aggregates
59:1203A—l204A (1987), has proposed a method for
composed of normal and paired helical ?laments and
detecting Alzheimer’s disease related amyloid protein in
presumably consist of several different proteins. The
the cerebral spinal ?uid of affected patients.

3
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biochemical marker and the identi?cation of such a

closes a diagnostic method for neurological and psychi

marker is needed.

atric disorders, such as Alzheimer‘s disease. The

method involves incubating cerebrospinal ?uid from a
patient in the presence of 32P-labeled adenosine triphos
phate (ATP) and a protein kinase which was capable of
transferring phosphate from the ATP, followed by elec

OBJECTS AND SUMMARY OF THE
INVENTION

5

It is, therefore, an object of this invention to provide
a method for diagnosing Alzheimer’s disease compris

trophoresis. The resulting autoradiographic pattern of

ing detecting a speci?c nucleotide binding protein
the fractionated, labeled sample is then compared with
predetermined autoradiographic patterns from known 10 within the extracted cerebral spinal fluid of patients
afflicted with Alzheimer’s disease.
neurological and psychiatric pathologies to ascertain
the particular pathology of the patient’s cerebrospinal

It is another object of the present invention to pro

?uid being analyzed. However, the method disadvanta
geously is based only on autoradiographic patterns. It
fails to identify disease-speci?c marker proteins in the
cerebral spinal ?uid.
Studies by Khatoon et al. (Ann. of Neurology,

vide a method for diagnosing Alzheimer’s disease com

prising detecting a speci?c nucleotide binding protein
within the extracted cerebral spinal ?uid of normal
patients, but which is not photolabeled in they cerebral
spinal ?uid of patients afflicted with Alzheimer’s dis

26:210-215 (1989)) have shown that an interaction of an

ease.

important cellular protein, tubulin, in the formation of

It is a further object of the present invention to pro
microtubules was aberrant in preparations made from
vide a composition for use in a test kit for the diagnosis
the brain tissues of patients with Alzheimer’s disease.
of Alzheimer’s disease comprising a radioactive pho
The inhibition was monitored by measuring the interac
toaf?nity probe which will selectively bind to a speci?c
tions of a radioactive photoaf?nity probe of the nucleo
nucleotide binding protein within the extracted cerebral
tide GTP (guanosine-S’-tri-phosphate) with the proteins
that require GTP to effect microtubule formation.
25 spinal ?uid of a patient af?icted with Alzheimer’s dis
Molecules containing azido groups have been shown
ease, but which is not found in the cerebral spinal ?uid
to form covalent bonds to proteins through reactive
of a normal subject.
nitrene intermediates, generated by low intensity ultra~
A still further object of the present invention is to
violet light. Potter & Haley, Meth. in Enzymol,
provide a composition for use in a test kit for the diag
91:613-633 (1983). In particular, 2- and 8-azido ana 30 nosis of Alzheimer’s disease comprising a radioactive
logues of purine nucleotides have been used as site di
photoaf?nity probe which will selectively bind to a
rected photoprobes to identify nucleotide binding pro
speci?c nucleotide binding protein within in the cere~
teins in crude cell extracts. Owens 8; Haley, J. Biol.
bral spinal ?uid of a normal patient, but which is not
Chem. 259:14843-14848 (1984); Atherton et al., Bio. of
Reproduction, 32:155-171 (1985). The 2-and 8-azido 35 found in the cerebral spinal ?uid of a patient af?icted
with Alzheimer’s disease.
,
nucleotides have also been used to map nucleotide bind
It
is
an
additional
object
of
the
present
invention to
ing domains of puri?ed proteins. Khatoon et al., Ann. of
provide antibodies to the respective Alzheimer’s disease
Neurology, 26:210-215 (1989); King et al., J. Biol.
related proteins, as identi?ed by the method of the cur
Chem. 264:10210-10218 (1989); and Dholakia et al., J.
Biol. Chem, 264:20638-20642 (1989).
rent invention, for the purpose of providing an immuno
Photoaf?nity probes have been used to determine
assay to recognize the Alzheimer’s disease speci?c pro
speci?c nucleotide binding sites on a biologically active
teins in the cerebral spinal ?uid, blood plasma, or tissues
recombinant peptide molecule. Campbell et al., PNAS,
of the human body.
87:1243-1246 (1990). The probes have also been used to
It is a ?nal object of the present invention to provide
study enzyme kinetics of puri?ed proteins. Kim et al., J. 45 a method, using the procedure of photoaf?nity labeling
Biol. Chem., 265:3636-3641 (1990).

with nucleotide af?nity probes, to diagnose neurologi
cal disorders using cerebral spinal ?uid, blood, tissue, or

Thus, considerable effort has been devoted to devel

oping systems for the de?nitive diagnosis of Alzhei
mer’s disease in patients. However, until the method of

other biological samples from a mammal. The presence
or
development of a neurological or psychiatric pathol
the, present invention, no reliable non-invasive test for 50
ogy including, but not limited to, Alzheimer’s disease,
Alzheimer’s disease has been developed. The major
epilepsy, scrapies-type disorders, amyotrophic lateral
drawback of the most de?nitive determination of Alz
heimer’s disease known in the art has been that direct
sclerosis (ALS or Lou Gehrig’s disease), Down’s syn

analysis of pathological tissue could only be performed
postmortem on affected individuals.

drome, Behcet disease, encephalitis, Huntington dis
55

Because Alzheimer’s disease is progressive in nature,
the ef?ciency of a cure could critically depend upon
early detection. Additionally, the value of any new
therapy in alleviating or curing the disease could be
better ascertained if a rapid, safe and effective diagnos 60

ease, Creutzfeldt-Jakob disease, Parkinson disease,
AIDS dementia, multiinfarct dementia, dystonia, ataxia,

schizophrenia, neurosyphilis, cerebral toxoplasmosis,

brain irradiation, brain tumor, Guillain-Barre syn
drome, tremor, multiple sclerosis, head trauma, acute
and chronic encephalitic and vascular disease can be
tic procedure were available to monitor the progress of
detected.
Alzheimer’s disease patients following treatment.
Additional objects, advantages and novel features of
Therefore, there remains a long-felt need in the art
the invention will be set forth in part in the description
for a reliable, accurate, safe and effective method for
the diagnosis of Alzheimer’s disease, as well as a means 65 which follows, and in part will become apparent to
those skilled in the art on examination of the following
for the differentiation of other neurological diseases and
syndromes or psychiatric pathology. A method for the
description, or may be learned by practice of the inven
tion.
identi?cation and characterization of a disease-speci?c

5
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detergent and subjected to protein fractionation, such as

DETAILED DESCRIPTION OF THE
PREFERRED EMBODIMENTS OF THE
INVENTION
In accordance with the present invention, novel com~
positions, methods and test kits are provided, using the

by gel electrophoresis. The ?nished gel is placed in a
holder containing X-ray ?lm for autoradiography. The

procedure of photoaf?nity labeling with nucleotide

radioactive protein (the result of chemical crosslinking
between the radioactive photoprobe and the binding
protein) in the gel can be located since the radioactivity
will expose the adjacent section of the ?lm resulting in

af?nity probes, to detect a neurological disorder using
cerebral spinal ?uid, blood, tissue, or other biological

a darkened (black) appearance.
The sample subjected to analysis can be selected from

samples from a mammal. The presence or development
of a neurological or psychiatric disorder can be de
tected. The invention concerns a composition, the prep

any biological sample capable of carrying the unique
nucleotide binding protein. Examples of such biological
samples include body ?uids such as spinal ?uid, blood

aration of the composition and a method for diagnosing
or detecting Alzheimer’s disease. The method involves
the use of a disease-speci?c nucleotide binding protein
within the extracted cerebral spinal ?uid of a patient

or serum. However, samples tested for the unique nu

cleotide binding protein by the present method are most
preferably cerebral spinal ?uid, also referred to as cere

brospinal ?uid.
The protein composition of cerebral spinal ?uid is

af?icted with a neurological disorder such as Alzhei
mer’s disease.
The present invention provides a method for detec
tion using a disease-speci?c biochemical marker macro
molecule which, if present, can be identi?ed in a small

largely derived from serum proteins which leak into the

subarachnoid space through imperfections in the blood
brain barrier, such as the area postrema, and perhaps

across the richly vascular choroid plexus, through

biological sample obtained from a patient. The speci?c

which cerebral spinal ?uid is generated as an ultra?l

biochemical marker macromolecule is dependent of the
neurological disease state which is being detected.
The standards are established by obtaining cerebral
spinal ?uid samples from a number of patients, each of
whom suffers from a particular neurological or psychi
atric disorder which is clinically manifested by marked

trate. The cerebral spinal ?uid has signi?cantly fewer
proteins than cytosolic fractions. Some proteins, such as
immunoglobulins, may be generated in the subarach
noid space during in?ammation. Since the cerebral
spinal ?uid bathes the surfaces of cerebral and cerebel
lar cortices, the caudate, brain stem and spinal cord,

dementia or de?ciency in cognitive function, including
memory or attention.

Speci?cally the neurological diseases of the nervous
system, referred to in the method of the present inven
tion are those diseases, disorders, or syndromes which
are either the cause of or the result of a biochemical

alteration in the brain, brain stem. spinal cord or gan
glia. The diseases can include, but are not limited to,

each of the structures contributes to the total cerebral
30

spinal ?uid protein.
The inventive method need not be limited to human
patients, but may be extended to any mammal afflicted
with certain neurological or psychiatric diseases or
syndromes, such as scrapies or “Mad Cow" disease.
The sample may be drawn as either ventricular cere

amyotrophic lateral sclerosis (ALS or Lou Gehrig‘s

bral spinal fluid or lumbar cerebral spinal ?uid. Occa
sionally, however, sample proteins are concentrated by
various procedures to better visualize the speci?c nucle

disease), Down’s syndrome, Behcet disease, encephali
tis, Huntington disease, Creutzfeldt-Jakob disease, Par

otide binding protein. Vacuum procedures include, for
example, lyophilization or Speed-vac concentration.

Alzheimer’s disease, epilepsy, scrapies-type disorders,

kinson disease. AIDS dementia, multiinfarct dementia,

Also, precipitation of cerebral spinal ?uid by ammo

dystonia, ataxia, schizophrenia. neurosyphilis, cerebral

nium sulfate or polyethylene glycol could be used to

toxoplasmosis, brain irradiation, brain tumor, Guillain
Barre syndrome, tremor, multiple sclerosis, head

concentrate the nucleotide binding proteins. Thus, there

disease-speci?c unique biochemical marker macromole
cule, in particular a speci?c nucleotide binding protein,

nucleotide introduced by replacing an equivalent non
radioactive atom with 32P, tritium, carbon-l4 or other

can be identi?ed in the spinal ?uid of patients suffering

radioactive atom or ligand analog modi?ed with a

from certain neurological disorders, particularly pa

linker group to provide a linking site to the crosslinking

tients suffering from Alzheimer’s disease.
Brie?y, a typical analysis of a cerebral spinal ?uid
sample by the method of the present invention would
proceed as follows. These steps and quantities are only
offered as guidlines for the practice of the present in

the present invention is a- or 732?.
The ligand or linker group, if present on the speci?c

are a variety of techniques well known in the art that
trauma, acute and chronic encephalitic and vascular 45 would be suitable in the practice of the present inven
disease. Moreover, the present method of detection
tion.
could also be used to monitor any event which causes
Detection of a specific nucleotide binding protein can
brain cell death which results in the accumulation of
be accomplished by measuring a label crosslinked to the
nucleotide binding proteins in the cerebral spinal ?uids,
selected biochemical marker macromolecule after reac~
such as, minor to severe brain damage caused by high
tion, photochemical or chemical crosslinking, and re
fever or head injury.
moval of free probe. The particular label bound to the
By the present invention it has been shown that a
macromolecule will include, for example, a' radioactive

vention.
A small portion, usually between 10 to 30 microliters
of cerebral spinal ?uid is mixed with concentrations of
about 10 to 30 uM of a radioactive photoaf?nity probe
for 0.5 to 1.0 minutes. followed by 30 to 120 seconds of

molecule. A particularly preferred radioactive label in
biochetnical marker macromolecule, will have chemical
characteristics or functionalities such that a small radio

active nuclide labeled molecule, or a chromogenic,
?uorogenic, or luminescent molecule, or a magnetic
particle can be attached to the ligand or linker group.

exposure to ultraviolet light. The sample is precipitated,

The ligand will have the chemical characteristics such
that a receptor molecule is available or capable of being
elicited, such as an antibody molecule to the ligand. The

then immediately solubilized with a solution containing

receptor molecule can be conjugated to a radioactive

5,272,055
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nuclide labeled molecule, or to a chromogenic, ?uoro
genic, or luminescent dye molecule, or to a magnetic
particle or to an enzyme system capable of generating a

chromogenic, fluorogenic, and/or luminescent product
via appropriate substrates.
Most preferably the unique biochemical marker mac

a pathway for the synthesis of other useful S-substituted
uridine nucleotides. The S-diazouridine nucleotides
may, for example, serve as active-site-directed photoaf
?nity probes or as substrates for polymerizing enzymes
to generate additional photoactive nucleic acids which
remain stable to extremes of pH and which remain ef
fective photolabeling reagents in the presence of reduc

romolecule, particularly the speci?c nucleotide binding
protein, is detected in the sample by a radioactively
labeled photoaf?nity probe. A nucleotide photoaf?nity
probe is a nucleotide derivative which has affinities for

binding sites and biological activity comparable to the
unaltered nucleotide. Exposure to certain wavelengths
of light converts the analog to a very reactive interme
diate, typically a nitrene or a carbene, which may result

ing agents. Moreover, since the synthesis of 5-N3dUTP
employs mild conditions, it is also possible to synthesize
homopolymers of 5-N3dUTP to provide single-stranded
photoactive DNA of de?ned length. Using 5N3UTP

in covalent incorporation into the binding site if it is
‘bound to a protein. .

There are certain advantages to using photoprobes
over conventional chemical probes. One advantage is
that K,,,, K4, and K; values can be determined in the

absence of activating light. Another advantage is that
complex systems such as ribosomes, membranes, and

8

Furthermore, photoaf?nity compounds of the present
invention may also include, for example, pyrimidine
derivatives. For instance, photoactive analogs of dUTP,
such as 5-azido-2’-deoxyuridine 5'-triphosphate (5
N3dUTP), may be synthesized from dUMP and provide

one can similarly produce photoactive RNA.
Generalized methods for the synthesis of aryl azides
include nucleophilic displacement of a bromine, chlo
20 rine or nitro group by an azide ion or the addition of

sodium azide to an acidic solution containing a diazo

whole cell sonicates can be studied. In this manner, an

tized primary aromatic amine.

in vivo situation may be more closely approximated and
To date the most widely used 8-azidopurine is proba
information may be obtained that might otherwise be
bly 8N3cAMP. One of the advantages of 8N3cAMP is
lost in a puri?ed system.
25 that in mammalian systems there are only two types of
Many nucleotide photoaf?nity probes may be synthe
proteins that are known to bind cAMP with high af?n
sized and used successfully. The photoaf?nity com
ity, the cAMP phosphodiesterases and the regulatory

pounds of the invention may include, for example, pu
subunits of the cAMP-dependent protein kinases. The
rine triphosphate azido analogs, which may be exempli
photoprobes [32P]8N3cAMP and [32P]8N3ATP have
?ed by adenine analogs, although guanine analogs can 30 been employed to study, for example, the mechanisms
be substituted therefor. For example, purine binding
of action of cAMP-dependent protein kinase. Photoac
sites may be effectively labeled by the following, and
tive analogs of GTP, e.g., [32P]8N3GTP, have been
their 5'-mono-, di- and triphosphates: oligomers of a
developed to study, for example, tubulin polymeriza
single azidoadenylyl species, such as, for example: 2
tion, while photoactive analogs of UTP, e.g.,
azido or 2-azidoadenylyl(2'-5’)2-azidoadenylyl(2’-5')2 35 [32P]5N3dUTP have been generated to study, for exam
azidoadenosine; 2-azido or 8-azidoadadenosine; 8

ple, the binding site of DNA binding proteins.

azidoadenosine:

synthesized from azidoadenosine 5’-triphosphates or
combinations thereof, which provide a (2’-5’)oligomer

azidoadenylyl(2’-5’)-8-azidoadenylyl(2’-5')8

Preferred compounds of the present invention are

8-azidoadenylyl(2’-5')-8

azidoadenylyl(2'—5’)8-azidoadenylyl-(2'-5')8

azidoadenosine;
2,8-diazidoadenylyl(2’—5')2,8
diazidoadenylyl(2’—5')2,8-diazido-adenosine;
2,8

containing both adenylyl and azidoadenylyl moieties. A
preferred photoaf?nity compound for the identi?cation

diazidoadenylyl(2'—5')2,S-diazidoadenyly1(2’-5')-2,8

by the present invention of the Alzheimer’s disease

diazidoadenylyl(2'-5’)-2,8-diazidoadenosine; also oligo

speci?c protein is 8-azidoadenosine 5'-triphosphate
(8N3ATP), while a particularly preferred photoaf?nity

mers of AMP and a single azidoadenylyl species, such

as,

for

example:

azidoadenosine;

2-azidoadenylyl(2’-5’)2-(2’—5‘)8

adenylyl(2'~5’)8-azido~adenylyl(

2'-5’)8-azidoadenosine; also oligomers containing more
than one azidoadenylyl species, such as, for example:

2-azidoadenylyl(2’—5’)8-azidoadenylyl(2'-5‘)2

45

compound of the present invention is 2-azidoadenosine

5'-triphosphate (2N3ATP). A particularly preferred
photoaf?nity compound for the identi?cation by the
present invention of the ALS-speci?c protein is 8

azidoguanosine 5’-triphosphate (8N3GTP).

azidoadenosine; also oligomers resulting from any com 50 Nonradioactive labels can be divided into two cate
bination of the monomers AMP, 2-azido-AMP, 8-azido
gories (i) chromogenic, ?uorogenic, or chemilumines
AMP and/or 2,8-diazido-AMP, provided that at least
cent dyes or (ii) ligands. Dyes are normally of from 8 to

one such monomer incorporated into the oligomer is an

azido-AMP species.
In addition photoaf?nity compounds of the invention
may also include photoactive coenzyme analogs of
NAD'*, exempli?ed by nicotinamide 2-azidoadenosine
dinucleotide (2-azido-NAD+), or analogs of NADH,

exempli?ed by nicotinamide Z-hydrazidoadenosine di
nucleotide (2-azido-NADH).
Alternately, guanine moieties can be de?ned in each

of the exemplary compounds in place of the respective

40 carbon atoms, preferably from 9 to 30 carbon atoms.

The dyes further normally contain from 1 to 10 hetero
55 atoms usually oxygen, nitrogen, or sulfur, and normally
contain no halogen atoms or up to 10 halogen atoms

usually iodine, bromine, chlorine, or ?uorine.

Chromogenic dyes may include phenolsulfonphthal
ein and analogs of tetrazolium.

Fluorogenic dyes may include ?uorescein isothiocya
nate, dichlorotriazinylamino ?uorescein, morpholinor
hodamine isothiocyanate, tetramethylrhodamine isothi

adenine moieties. Therefore, certain most preferred
ocyanate, and 4-acetamido-4-isothiocyanostilbene-2
compounds of the present invention are synthesized
with 2’-disulfonic acid. Fluorescent purine derivatives
from azidoguanosine 5’-triphosphates or combinations 65 may also include, for example, the fluorescent GTP
thereof, or from azidoguanisine 5’-triphosphates and
analog 2'3'-O~(2,4,6-trinitrocyclohexadienyl-idine)
ATP. The latter provides a (2’-5')oligomer containing
guanosine 5'-triphosphate (TNP-GTP), or the equiva
both guanylyl and azidoguanylyl moieties.
lent ?uorescent ATP derivative (TN P-ATP).
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by thin-layer chromatography, e.g., by ?uorescent cel
lulose thin-layer chromatography.

Chemiluminescent dyes may include 5-amino-2,3

dihydro-phthalazine-l,4-dione (luminol), derivatives of

Ionic strength, pH, cofactor, and metal ion concen

isoluminol and acridinium esters.

Any ligand may be employed for which an appropri

trations can each affect protein structure, and are

ate receptor may be found to have satisfactory speci?c

readily adjusted by those skilled in the art to achieve
optimal labeling conditions. In addition protein concen

ity for the ligand.

tration can be determinative of the photoresponse. The
higher the protein content of the sample, the denser the
solution becomes to light. Therefore, in a denser solu

Various methods or protocols may be employed in
measuring the amount of the labels. These protocols can

include for example, radioimmunoassay (RIA), im
munoradiometric assay (IRMA), sandwich IRMA,
?uoroimmunoassay (FIA), chemiluminescent assays,

tion, less UV light reaches the photoreagent per unit of
time, decreasing the rate of photoincorporation. Aggre
gation of the protein can also affect the binding time of

bioluminescent assays, and enzyme linked immunosorb
ent assays (ELISA) among others.
The labeled probe of the present invention can be

used in any conventional hybridization technique. Hy
bridization formats which may be useful in the practice
of the present invention include those in which the
sample is immobilized on a solid support (solid-phase
hybridization) and those wherein the species are all in

solution (solution hybridization). Solution hybridization
is preferred in the present method. Another method of
interest is the sandwich hybridization technique.

the reagent to the protein, thereby increasing or de

creasing photoincorporation. One must experimentally
redetermine optimal photolysis time when changing
protein concentration if maximum incorporation of the
photolabel is desired.
By the present invention, it is preferable to photolabel
a small 10 to 30 microliter aliquot of cerebral spinal ?uid
N0

with radioactively-labeled photoaf?nity probe (i.e.,
[32P]2N3ATP or [32P]8N3ATP) resulting in an approxi
mate ?nal concentration of 10 to 30 uM for detection of

the Alzheimer’s disease-speci?c 42,000M, protein. Most
Certain factors are considered when a unique bio
preferably, the aliquot of each cerebral spinal ?uid ana
chemical macromolecular marker is identi?ed by means
5 lyzed is 15 ul. However, limits of detection are im
of a radioactive photoaf?nity label, as is the preferred
proved, at little expense, by using larger sample vol
method of the present invention. For example, consider
ation should be given to: (a) temperature of incubation

and photolysis, (b) length of incubation and photolysis,
(c) concentration of photoaffmity reagent, (d) binding
af?nity of protein for the reagent and natural ligands,
(e) stability of the photoaf?nity reagent in each particu
lar system, (f) ionic strength, pl-l, cofactors, (g) protein

concentration, (h) intensity of photolyzing light, (i)
quenching of reaction and separation of unused label,
and (j) interpretation of results. Potter 8: Haley in Meth.
in EnzymoL, 91:613-633 (1983) provide a detailed ac

count of preferred procedures for labeling a speci?c
biochemical marker macromolecule in a sample with a

photosensitive purine triphosphate azide analog.
Temperature of the photolysis reaction between the

umes or by concentrating the spinal ?uid.
In the alternative, the sample may be labeled with
[32P]8N3cAMP, in which case the sample is placed on
ice to reduce the temperature to about 0° C. and photo
activated. In experiments conducted to evaluate the

absence of [32P]8N3cAMP photoinsertion into the pro
tein of interest in a cerebral spinal ?uid sample, the

preferred concentration of [32P]8N3cAMP is main
tained at not more than 5 uM.

Detection of the labeled protein occurs following an
appropriate, predetermined incubation time to effect a
reaction, and is calculated on the basis of the sample and

the selected photoaf?nity probe.
The intensity of the photolyzing light is such that
maximum photoincorporation can be obtained in a mini

sample and the selected photoaf?nity label can range
mum amount of time without appreciable change in
from 0c C. to room temperature (25° C.) or above. How
temperature or damage to the biological sample. Prefer
ever, the exchange rate between bound and unbound
ably the photolysis is achieved at 254 nm with an ultra
cAMP or 8-N3cAMP approaches negligible levels at 0° 45 violet light source.
C., and is greatly increased at room temperature. Con
Ultraviolet (UV) light is essential for the activation of
versely, once 8-N3CAMP is bound to the speci?c mac~
the photoprobe treated samples, but only a low intensity
romolecular marker, it may be cold trapped onto the
UV light is necessary. The intensity of the UV light can
protein by dropping the temperature to nearly 0° C.
range from 180 to 800 uW/cm2 by conventional sources
Therefore, the most preferred procedure includes prein
to 4000 uW/cm2 and above when a high intensity
cubation of the components at room temperature, and
source is used to achieve rapid photolysis.
photolysis in plates set on ice to reduce the temperature
Photolysis times range from 15 seconds to 5 minutes
to approximately 0° to 4° C. By the present invention,
and must be experimentally determined for each reac~
the sample is preferably incubated at room temperature
tion system. For lamps having intensities of l80—800

with the radioactive photoaf?nity probe for approxi

mately 0.5 to 1.0 minutes. Most preferably the mixture is
vortexed for 6 seconds followed by an additional 24

seconds of mixing, immediately followed by placing the
sample on ice for photoactivation.
The concentration of photoaf?nity reagent must be
compatible with the binding af?nity of the protein to be
labeled. Excessively high concentrations, however, can
lead to undesirable nonspeci?c labeling which increases

uW/cm2, the preferred photolysis time ranges from
approximately 30 to 120 seconds, most preferably, pho
tolysis is effected in approximately 30 to 60 seconds.
The distance of the light source from the sample is a
determinative factor in the conditions of photolysis. A
preferred method of the present invention uses an ultra

violet light source having suf?cient intensity, about
6200 uW/cmZ, positioned at a set distance, about 1 cm
from the sample, for a time sufficient to effect photoac

linearly with concentration. Best results can be obtained

tivation, generally approximately 45 seconds.

by experimentally determining the optimum concentra

The labeled macromolecule is typically separated
from the solution containing excess unbound sample
and/or label by precipitation, although other recog
nized methods of protein puri?cation are possible. Rec

tion for photoincorporation. Directly related to the
determination of concentration is the stability of the
reagent. The stability of the reagent can be determined

11

5,272,055

ognized methods of precipitation include, but are not
limited to addition of an effective protein precipitating
agent, such as trichloroacetic acid (TCA), perchloric

12

present method, protein separation is usually by electro
phoresis on a denaturing gel.
The nature of the sample and the size of the speci?c

acid (PCA), acetone, ammonium sulfate, polyethylene

nucleotide binding protein determine the concentration

glycol (PEG) or the like to the sample. PCA or ammo
nium sulfate are the preferred precipitating agents in the

of the gel used, which in turn determines the time for
separation and the electrical current which must be

present method, and PCA is the particularly preferred

applied to best achieve protein separation. The protein

precipitating agent.

fractions of the present invention are most preferably

The amount of precipitating agent is determined by
the concentration of protein in the sample. The pre
ferred concentration of the precipitating agent is that
concentration which effectively precipitates the spe
ci?c protein from solution. The most preferred concen
tration of the precipitating agent is that amount which

separated by electrophoresis on an SDS-polyacryla

electrophoresis equipment can be utilized.

effectively precipitates the previously activated,
photolabeled cerebral spinal ?uid sample.

The resultant gels are exposed to X-ray ?lm and
visualized by autoradiography according to methods

The precipitating agent can be mixed with the sample

well known in the art. The gels can also be stained to

mide gel (SDS-PAGE). Typically, the sample is frac
tionated on a 10% polyacrylamide gel, run over a per

iod of 2} to 3 hours, with constant amperage of 35 mA
and an initial voltage of about 140 volts. Any standard
'

as a dry batch addition or in a calculated equivalent

determine the presence of the unique specific protein

liquid form. The required mixing time may vary with

band or to ascertain that differences in the amount of

the nature of the agent selected and the size or concen

photolabel incorporation are not due to drastic changes

in the protein levels. Many known protein staining

tration of the sample. However, the time required is that
point after which essentially no additional protein is
precipitated from the sample solution at the tempera

methods are widely recognized, e.g., Coomassie Bril
liant Blue R (CBB) or silver staining. CBB is a com
monly used stain that detects proteins based on a hydro

ture selected.

The precipitated protein may be separated from solu 25 phobic interaction between the proteins and the dye.
Although any available staining method can be used
tion by any effective means, such as centrifugation,

which effectively distinguishes the speci?c nucleotide

sedimentation or ?ltration. The preferred method of

binding protein, CBB is the fastest and most economical
for the present method.

separation of the precipitated protein from the solution
is by centrifugation at a suf?cient speed and for a suffi
cient time to effectively isolate the protein into a pellet.

Most preferably, each completed SDS-PAGE gel is
stained with an effective amount of CBB to stain the

The most preferred method of separation is centrifuga

selected protein fragments. In particular, the completed

tion at 13,000 X G for 30 minutes. However, the parame

gel is immersed in a 10% CBB (w/v) solution for about

ters vary with the nature of the solution.

1 hour. Then the gel is destained in a solution to effec
tively remove excess stain. Particularly preferred is a

To determine the effectiveness of the precipitation
and separation procedures, both the pellet and the su
pernatant ?uid are analyzed for protein content.
The precipitated protein may be solubilized and any

destaining solution of 5% acetic acid and 10% isopropyl
alcohol applied for 10-18 hours.

remaining reaction quenched by any effective, known

be visualized by standard autoradiography techniques.

Finally, the speci?c binding protein fragments may

method. The determination of the solubilizing agent
would depend on the ultimate method of identifying the

The use of an intensifying screen effectively accelerates

speci?c nucleotide binding protein. Therefore, such
agents could include, e.g., sodium dodecyl sulfate
(SDS) or urea, and certain stabilizing agents.

Any azide remaining after photolysis may be de
stroyed by the addition of dithiothreitol or its equiva

lent, and potential phosphotransfer from the tn'phos
phate derivative N3ATP or N3GTP may be inhibited
by chelators such as EDTA. The preferred protein

solubilizing agent is a detergent, particularly SDS, most
preferably in a protein solubilizing mix (PSM), such as
described by Potter & Haley in Meth. in Enzymol.,
91:613-633 (1983) or by procedures standard to most

published procedures. A particularly preferred concen

45

the visualization process of autoradiography. By the
method of the present invention, the stained gel is dried,
and then exposed to DuPont Cronex 4 X-ray ?lm. The
autoradiographic procedure is for variable time periods
depending on the speci?c activity of the probe photoin
serted into the proteins of each experimental sample.
Alternately, if maintained at —70° C., the gel can be
subjected to autoradiographic procedures while still in
the gel state.
The amount of protein, as well as the radioactivity

incorporated into each protein, can be quanti?ed by
known methods including, but not limited to, densito
metric scans of the exposed X-ray ?lm, or of the stained

gel, or by liquid scintillation spectrometry of the protein

tration of SDS in the mix is 10%, resulting in a concen 55 band following excision from the gel.
tration of SDS to the ?nal sample of 4%.
Analyses of cerebral spinal fluid taken from human
Solubilization can occur either at 0° C. or at higher

temperatures without affecting the results. However,
solubilization in the present invention is effective at
room temperature.

Upon solubilization, the protein sample is applied to a
suitable support for separation of the protein fractions.
Support materials could include, e.g., polyacrylamide
gels, ?lter paper, starch gels or blocks, cellulose or

patients suffering from certain neurological or psychiat
ric diseases or disorders, when labeled with the appro

priate, subsequently activated, radioactive photoaf?nity
probe, reveals a disease-speci?c biochemical marker by
which an existing disease state can be characterized.

For example, a protein band having an apparent molec
ular weight of about 68,000 Dil0% is found in the
cerebral spinal ?uid of normal human subjects, visual

polyurethane foam. Any effective, known method of 65 ized by a subsequently activated, radioactive photoaf
protein separation may be used, but preferably separa
?nity probe, e.g., [32P]8N3cAMP. More particularly,
tion is by electrophoresis over denaturing or non
the identi?ed protein band has an approximate molecu
denaturing gels, or over a gradient of either type. In the
lar weight of 68 kD. Moreover, a fragment of the same
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size is recognized in cerebral spinal ?uid samples taken
from patients af?icted with neurological diseases other
than Alzheimer’s disease.

By comparison, the cerebral spinal ?uid of human
patients suffering from Alzheimer’s disease, is charac
terized by an absence of photodetection of the protein
fragment having an approximate weight of 68 kD, as

visualized

by

photolabeling

by,

for

14

beling of the 68 kD protein of normal, control sample
cerebral spinal ?uid with [32P]8N3cAMP.
By the present invention, the Alzheimer’s disease
speci?c 42,000 M, protein could be further identi?ed as

glutamine synthetase. Mammalian glutamine synthetase
is an enzyme with 42,000 M, subunits that catalyzes the

following reaction:

example,

[32P]8N3cAMP.

Furthermore, the cerebral spinal ?uid of human pa - 0
tients suffering from various neurological and psychiat
ric disorders, labeled with a subsequently activated,
radioactive photoaf?nity probe, is found to have unique
speci?c nucleotide binding proteins which can provide
a distinctive means of diagnosing particular diseases.
For example, a characteristic protein band having an

glutamate +NH4+ ATP-glutamine +ADP+Pi

Further, it has been suggested that metabolism of gluta
mate is altered in Alzheimer’s disease (AD) since those
sections of the diseased brain which have become dys
functional show very low levels of glutamate. More
over, the neuronal cells that die in Alzheimer’s disease
patients are glutamate sensitive cells.

_

Glutamine synthetase can also be detected by measur

apparent molecular weight of about 42,000 D;+:10% is
found in the radioactive photoaf?nity labeled cerebral

ing the enzymatic catalytic conversion of substrates to

spinal ?uid of Alzheimer’s disease patients using
[32P]8N3ATP. More particularly, the Alzheimer’s dis

products. Recognized detection techniques include, for
example, measuring the catalytic conversion of
["C]glutamate to [14C]glutamine or [a32P ]ATP to

ease-speci?c identi?ed protein band has an approximate
molecular weight of 42 kD.
By comparison, a systematic survey of the cerebral
spinal ?uid taken from normal human subjects and la
beled with a similar subsequently activated, radioactive

invention.

photoaf?nity probe (i.e., [32P]8N3ATP), shows no pro
tein fragment having an approximate weight of 42 kD
being photolabeled. Thus, the identi?ed protein is

The 42,000 M ,protein is present in the cerebral spinal
?uid of Alzheimer’s disease patients in very small quan
tities. However, other than albumin and a protein of

unique to Alzheimer’s disease patients. There is appar
ently no identi?ed corresponding protein fragment con
tained in the cerebral spinal ?uid of normal human

about 28,000 M,, the 42,000 M, protein is the major

subjects.

using the technique of photoaf?nity labeling and the

[a32P]ADP. Such methods of measuring catalytic con
version are applicable to the detection of the Alzhei

mer’s disease-speci?c 42,000 M, protein of the present

protein known to photolabel with either 8N3ATP or
2N3ATP at the concentrations used. Therefore, by

materials and methods of the present invention, it is
In addition to being photolabeled with the radioac
tive photoprobe, the 42,000 M ,protein may be shown to 35 possible to detect a very minor protein of cerebral spi
nal ?uid that interacts with ATP and GTP, and which
interact with ATP, a naturally occuring nucleotide that
appears to be unique in the cerebral spinal ?uid of clini
is the phosphate donor for many protein kinases and
cally diagnosed Alzheimer’s disease patients.
synthetases. Therefore. based on the selectivity, the
A recently completed set of studies by the inventor of
Alzheimer's disease-specific protein may be identi?ed as
the present application have permitted the optimization
an ATP binding protein of about 42,000 M,. Further
more, the same 42 kD protein can be photolabeled with

of photo-incorporation into a protein. Thus, it is now

8-azido-GTP, de?ning the speci?c protein as an ATP

possible to label 10-15 microliters of sample with thou

and GTP binding protein. However, the 42,000 M,
protein binds ATP with higher af?nity.
Therefore, the human cerebral spinal ?uid samples

sands of cpms of 32F, signi?cantly enhancing the puri?

can be reliably and accurately distinguished into two
groups. The cerebral spinal fluid samples taken from

Post-mortem studies have shown that the identi?ed
42,000 M, protein present in Alzheimer’s disease pa
tients photolabels at high levels in the ventricular cere
bral spinal ?uid, but only at low levels in the lumbar
cerebral spinal ?uid. However, since the method of the

Alzheimer's disease patients show photoinsertion of
[32P]8N3ATP or [32P]2N3ATP into the identi?ed dis
ease-speci?c 42 kD protein, but an absence of photoin
sertion of [32P]8N3cAMP in the normal 68 kD protein.
Whereas, the samples taken from control subjects, unaf
?icted by Alzheimer’s disease, show photoinsertion of

cation of the protein and further improving its value as
a diagnostic tool.

present invention advantageously permits identi?cation
and puri?cation of the speci?c nucleotide binding pro

[32P]8N3cAMP into a normal 68 kD protein, but no

tein from only minute microliter amounts of cerebral
spinal ?uid, the labeled 42 kD protein can be detected in

photoinsertion of either [32P]8N3ATP or [32P]2N3ATP

samples containing only very low levels of the protein.

Additionally, recent results using 1 ml aliquots of lum
bar cerebral spinal ?uids treated with 40% ammonium
sulfate saturation gave a protein precipitate that con
tained easily detectable amounts of the 42,000 M, pro
with a GTP analog, confirm the results observed when
the 42 kD protein is photo-labeled with the photoaf 60 tein on photolabeling with [32P]2N3ATP. This con?rms
that lumbar cerebral spinal ?uid can be used in this
?nity probe of ATP.
diagnostic test.
Based on mixing experiments of cerebral spinal ?uid
By a similar procedure, a protein band having an
taken from control subjects (in which the 68 kD protein
apparent molecular weight of about 55,000 D is found in
is photolabeled) and samples of Alzheimer’s disease
patients‘ cerebral spinal ?uid (in which the 68 kD pro 65 the cerebral spinal ?uid of amyotrophic lateral sclerosis
(ALS or Lou Gehrig’s disease) patients, visualized by a
tein does not photolabel), it may be shown by the pres
into a 42 kD protein. The comparative analyses of cere

bral spinal ?uid samples from Alzheimer’s disease pa
tients and from normal human subjects, photolabeled

ent invention that a component of the Alzheimer’s dis

subsequently activated, radioactive GTP photoaf?nity

ease cerebral spinal ?uid apparently prevents photola

probe. Moreover, the unique ALS-speci?c 55,000 M,

15
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protein is not found in the cerebral spinal fluid of either
normal subjects or patients with Alzheimer’s disease.
Therefore, the unique variations in the pattern of

photolabeled protein fragments found in a small sample
of a patient’s cerebral spinal fluid provides the key to
identifying an existing disease state affecting the patient.
The compositions, methods, and test kits of the present
invention, when applied to minute amounts of cerebral
spinal fluid sample, can photolabel and detect the dis
ease-speci?c biochemical marker by which a particular
disease state may be identi?ed in a patient.

collected and immediately photolabeled cerebral spinal
?uid displayed the same characteristics as frozen sam

ples stored for extended periods of time. Fresh cerebral
spinal ?uid samples were collected from cadavers
within a few hours of death. Frozen samples were

shipped on dry ice from suppliers, Eli Lilly, Inc. and
Athena Neurosciences, then stored at —20° C. until

assayed. For each experiment, the sample was thawed
completely, an aliquot was withdrawn, then the sample
bl 0 was immediately refrozen and returned to ~20’ C.

storage. Samples were handled with gloved hands at all

The novel method of the present invention incorpo
rates a dual system of comparison in order to diagnose
the disease state. It is not enough that a speci?c disease
state is recognized simply by the apparent absence of a
speci?c protein. A ‘conclusion based on only the ab
sence of a result could prove erroneous. For example,

the protein could actually be present, but not properly
photolabeled because of procedural errors.
By the present invention the diagnosis is based on
both the presence of a unique disease-speci?c binding
protein or biochemical marker in a sample of body ?uid
from a diseased patient, and the absence of a “normal"

binding protein or biochemical marker characteristi

cally found in samples from normal subjects. Therefore,
the present inventive method has met a long-felt need in
the art for a reliable, accurate, safe and effective method

times.

l

Each assay was perfonned on 15 pl of cerebral spinal
?uid. Although the amount of cerebral spinal ?uid
tested remained constant for each experiment, the pro
tein concentration of each sample varied to some de

gree. However, the slight protein variation showed no
effect on the outcome of the experiment.

Occasionally, lumbar cerebral spinal ?uid samples
20 from some Alzheimer’s disease patients contained too

little of the 42,000 M, protein to be visualized. Those
samples were concentrated using vacuum procedures,

lyophilization or Speed-vac concentration, prior to
photolysis or by precipitation of proteins by ammonium
25 sulfate or polyethylene glycol or the like.

Concentration increased the visibility of the 42,000
M, protein in cerebral spinal ?uid samples from Alzhei

which distinguishes Alzheimer’s disease patients from
both normal subjects and patients afflicted with other

mer’s disease patients, but did not make the correspond

neurological or psychiatric disorders or dementias.

spinal ?uid from normal, control subjects. Moreover,

Moreover, the invention advantageously has also met
the equally long-felt need for a reliable, accurate, safe
and effective method to detect disease-speci?c bio
chemical markers for other neurological syndromes or
diseases, such as ALS, in a patient so afflicted.
In order that those skilled in the art can more fully

understand the present invention and advantages
thereof. the following examples are set forth. These

examples are given solely for the purpose of illustration,

ing 42,000 M, protein band detectable in the cerebral
following the vacuum concentration procedure, the

68,000 M, proteins no longer photolabeled with
[32P]8N3ATP. However, the effect was shown not to be

generalized since photolabeling of the 26,000 M, pro
tein, apparently present in all cerebral spinal ?uid sam
ples, did not decrease following vacuum concentration.
As a result, the 42,000 M, protein was more readily
visible since it was one of only two major photolabeled

species. Usually 1 ml of the cerebral spinal ?uid sample

and should not be considered as expressing limitations 40 was evaporated under vacuum conditions to a ?nal
unless so set forth in the appended claims.
volume of about 0.2 to 0.3 ml, resulting in an increased

EXAMPLES
Standard procedures and reagents were used in ac

cordance with Maniatis et al. (1982) Molecular Cloning:

A Laboratory Manual, Cold Spring Harbor Labora
tory, New York. Speci?c techniques for the photoaf
?nity labeling of speci?c nucleotide binding sites with

detection of the 42,000 M,protein of about 3- to 5-fold.
Ammonium sulfate precipitation of 40% saturation of a

1 ml aliquot of lumbar cerebral spinal ?uid increased
detection at least 10 to 20 fold.

Each cerebral spinal ?uid sample was photolabeled

with [32P]8N3ATP to identify the 42,000 M, protein.

The cerebral spinal ?uid sample was comprised to cere
purine phosphate azide analogs were used in accor
bral spinal ?uid, buffer, and water. The photoprobes
dance with Potter & Haley, Meth. in Enzymol., 91: 50 used in each experiment were prepared by the inventor

613-633 (1983). Approximate molecular weights were

represented as migration rates (M,) values as estimated
from plots of the migration rate versus the log molecu
lar weight of commercial protein standards. Each sam
ple was analyzed at least three times to ensure accurate
results.

Example l-Puri?cation of the Cerebral Spinal Fluid
Protein

The diagnostic proteins of the present invention were
characterized using the results of blind assays of cere

bral spinal ?uid samples from 40 patients having condi
tions diagnosed as Alzheimer‘s disease, Parkinson‘s
disease or epilepsy, and corresponding age matched

according to the procedures disclosed by Potter and
Haley in Meth. In Enzymol, 91:613-633 (1983). Probes
were also available commercially through ICN Radio

chemicals 2727 Campus Drive, Irvine, Calif. 92715.
Several concentrations of [32P]8N3cAMP were used
in the various experiments. The concentrations varied
from 1 uM to 10 uM, but produced no signi?cant varia
tion in the results. Photo-labeling differences were most
apparent at low concentrations of [32P]8N3cAMP with
the Alzheimer’s disease 68,000 M, protein, wherein the
degree of photoinsertion was much less than that of the

comparable control 68,000 M, protein. The decreased
availability of the 68,000 M, protein in Alzheimer’s
disease patient samples is very concentration depen
dent, with virtually no observable photoinsertion below

controls.
65
The cerebral spinal ?uid samples were stored at —20°
a 5 }LM concentration of [32P]8N3cAMP.
C. for various periods of time without adversely affect~
In each experiment, photoprobe was added to the

ing the experiments. Experiments conducted on freshly

‘cerebral spinal ?uid sample and vortexed for 6 seconds.
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Each treated sample was then allowed to mix for an
additional 24 seconds at room temperature before expo

18

ti?ed by densitometric scans of the exposed X-ray ?lm,
or of the stained gel, or by liquid scintillation spectrom
etry of the protein band excised from the gel. Signi?

sure to ultraviolet (UV) light.
The treated samples were placed on ice and exposed

cance was determined by analysis of variance at a rho

to UV light for 45 seconds. The UV light source, a

level below 0.50.

hand-held UV lamp with an intensity of 6200 uW/cmZ,

From among the 40 samples analyzed under blind
condition, all 16 cerebral spinal ?uid samples from Alz

was positioned 1 cm from the sample. The UV activa

tion of the photoprobe labeled samples was always

heimer’s disease patients showed photo-insertion by
[32P]8N3ATP into the 42,000 M, protein. By compari
son, only two “control” samples showed photoinsertion

conducted at 0° C.

The samples were precipitated by the addition of 6%
perchloric acid or by the addition of increasing amounts
of ammonium sulfate. Precipitation by ammonium sul
fate was used to purify the protein for further character
ization of the protein found in the Alzheimer’s disease
cerebral spinal ?uid or for antibody production. The
protein precipitated ‘by each ammonium sulfate addition
was saved for electrophoretic analysis and autoradiog

into the 42,000 M, protein, but the samples were from
subjects aged 86 & 94, who had not been identi?ed as
free of Alzheimer’s disease. Only 3 samples, each pro
vided by the same laboratory, failed to demonstrate
photoinsertion as expected. Furthermore, the speci?c
42,000 M, protein was found absent in the remaining 19

cerebral spinal ?uid samples, consisting of about equal

raphy.
The percentage of ammonium sulfate that precipi
tated the identi?ed protein was suf?ciently specific that

numbers of samples from control subjects or from pa
tients affected by Parkinson disease or epilepsy.
20

it was used as a factor to characterize the protein and its

properties. Therefore, by combining the ammonium

Example 2-Photolabeling of Cerebral Spinal Fluid
Samples with ['y32P]8N3ATP.

sulfate precipitations from before and after photolabel‘
Comparative cerebral spinal ?uid samples were ob
ing. the 42,000 M, protein was concentrated from large
tained from Athena Neurosciences from patients known
volumes of cerebral spinal ?uid. Simultaneously, most 25 to have epilepsy, Parkinson’s disease or Alzheimer’s
of the contaminating proteins were removed.
disease (AD), or from normal control subjects. The
The 42,000 M, protein was precipitated by a 40%
ammonium sulfate saturation. The calculated amount of

samples

were

processed,

photolabeled

with

['y32P]8N3ATP and analyzed according to the proce
dures of Example 1. However, in an autoradiograph of

solid ultrapure ammonium sulfate necessary to result in
40% saturation was added to each previously activated, 30 an SDS-PAGE gel on which the proteins in the cere
photolabeled cerebral spinal ?uid sample. The mixture
bral spinal fluid samples were screened in a blind man
was stirred gently for 30 minutes at room temperature,
ner, a protein of about 42 kD was photolabeled only in

then centrifuged in a table top centrifuge (13,000XG)
for 30 minutes to separate the puri?ed protein. Small
aliquots of each supernatant and pellet were analyzed
for protein content by SDS-PAGE.
The puri?ed protein samples were solubilized in a
protein solubilizing mix (PSM), standard to most pub
lished procedures. The concentration of SDS (sodium
dodecyl sulfate) in the mix was 10%, resulting in a
concentration of SDS to the ?nal sample of 4%. Sam
ples were solubilized in each experiment at room tem

perature.
Each sample was fractionated by 10% SDS-PAGE,

the samples from Alzheimer’s disease patients.

Example 3-Photolabeling of Cerebral Spinal Fluid

Samples with [32P]8N3cAMP.
The comparative cerebral spinal ?uid samples were
the same as those used in Example 2, from patients
known to have epilepsy, Parkinson’s disease or Alzhei~
mer’s disease (AD), or from normal control subjects.

The samples were processed, photolabeled with
[32P]8N3cAMP and analyzed according to the proce
dures of Example 1.

Two matched SDS-polyacrylamide gels were run to
run over a period of 2% to 3 hours, with constant amper 45 separate the cerebral spinal ?uid proteins in each sample
age of 35 mA and an initial voltage of 140 volts. Since
after photolabeling with [32P]8N3cAMP. Gel I was
all of the proteins were very well separated on a 10%
stained with CBB, then exposed to X-ray ?lm and ana
gel, a gradient was not necessary.
lyzed by autoradiography. Gel ll was stained and ana

The completed SDS-PAGE gels were stained to

lyzed by autoradiography.

detect the protein before exposing the gel to X-ray ?lm.

The CBB stained gel showed that there were several

Coomassie Brilliant Blue R (CBB) proved to be the
fastest and most effective stain for protein detection in

proteins found in the cerebral spinal ?uid. The protein

these experiments. Each completed SDS-PAGE gel

levels did not change when comparisons ‘were made
between Alzheimer’s disease and control samples.

was stained with a 10% CBB (w/v) solution for about 1
hour, then destained in a solution of 5% acetic acid and

that the amount of [32P]8N3cAMP photolabel incorpo

10% isopropyl alcohol for 10-18 hours, then washed
three times to remove that portion of the photoaf?nity
label which had not crosslinked with the speci?c nucle

otide binding protein.
Finally, the stained gels were dried and exposed to
DuPont Cronex 4 X-ray ?lm. The autoradiographic
procedure involved variable time periods depending on

the speci?c activity of the probe photoinserted into the
proteins of each experimental sample, and the presence
of an intensifying screen to accelerate visualization of 65

the speci?c protein band.
The quantity of protein, as well as the amount of the

radioactivity incorporated into each protein, was quan

However, by comparison, the autoradiographs show
rated into each protein did vary between Alzheimer’s
disease and control samples. Notably, more bands ap
peared on the stained gel than on the exposed X-ray ?lm
because not all cerebral spinal ?uid proteins were sub
ject to photoinsertion. A protein of about 68 kD was

photolabeled only in the samples from patients diag
nosed as not having Alzheimer’s disease. In contrast, a

protein of 42 kD was photolabeled with [3ZP]8N3ATP
only in samples from Alzheimer’s diseased patients.
The differences between the stained gel and the ex

posed autoradiographic ?lm demonstrated that photola
beling of a protein is a very speci?c and reproducible
process. The experiments have shown that each

19
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photolabeled disease-speci?c protein band has essen
tially the same M, value, with slight variations due only

20

4. A nearly identical mole to mole ratio of photoinser
tion was noted with both GS and the cerebral spinal
?uid 42 kD protein from Alzheimer’s disease patients.
Both' proteins showed the same relative photoinsertion

to minor variations in the gel itself.

Example 4-Puri?cation of the Alzheimer’s
Disease-Speci?c 42 kD Binding Protein.
The 42 kD cerebral spinal ?uid protein was isolated
as a pure fraction by the following high performance

ef?ciencies of 8-azido-ATP versus 2-azido-ATP. In

particular, the amount of photo-incorporation into both
GS and the 42kD protein found in the cerebral spinal
?uid from Alzheimer’s disease patients was greater on a
mole to mole basis when [732P]2N3ATP was used as a

liquid chromatography (HPLC) procedure. The cere
bral spinal ?uid from Alzheimer’s disease patients was

photolabel, rather than the structurally different ATP

photolabeled and the protein fraction was precipitated

analog ['y32P]8N3ATP.

by ammonium sulfate at 20 to 40% saturation. The

5. Both puri?ed GS and the 42kD protein found in
the cerebral spinal ?uid from Alzheimer’s disease pa

precipitated proteins were solubilized in Buffer A [0.1%
tri?uoroacetic acid (TFA)] and subjected to HPLC on
a C4 column with the following acetonitrile gradient:
0-20 minutes at 0% buffer B; then 20-80 minutes at
increasing percentages of buffer B to 100%, wherein
buffer B was 0.1% TFA and 70% CH3CN (acetoni

trile).
The 42 kD protein was eluted at approximately
82-92% B. The fraction was also radioactive if the

sample was photolyzed with [32P]2N3ATP or [-y
32P]8N3ATP prior to the ammonium sulfate precipita
tion. The purity and identity of the fraction was con

?rmed by SDS-PAGE of the fraction and autoradio
graphic visualization. Therefore, it was concluded that

tients were labeled with a secondary radioiodinated- >

antibody known to be reactive to an antibody selective

for GS (rat brain) in a Western blot. However, other
cerebral spinal ?uid proteins and creatine kinase did not
crossreact with this GS antibody. Therefore, antibody
selective for GS also reacted with the 42kD protein of
the cerebral spinal ?uid from Alzheimer’s disease pa
tients.
6. The elution pattern of both the 42kD protein and
puri?ed GS was nearly identical on HPLC chromatog
raphy using a C4 column and acetonitrile gradient as
25 described in Example 4. Both eluted at about 75-85%
buffer B.

the puri?ed protein was subject to photoinsertion and

7. On 2-dimensional gel electrophoresis (IEF X SDS
PAGE) the 42kD protein in the cerebral spinal ?uid
from Alzheimer’s disease patients was a single species,
Example S-Identi?cation of the Alzheimer’s
30 having a pI value of 60:02 pH units. By comparison,
Disease-Speci?c 42,000 M, Protein Found in Cerebral
with the puri?ed GS from Sigma the pl range of the
Spinal Fluid.
major protein species at 42,000 M, value was 5.8-7.2

had a molecular weight of 42,000 kD.

Based on the following evidence, the Alzheimer’s

and consisted of 6 isoelectric forms. The most acidic of
the isoelectric forms migrated on 2-dimensional gels

disease-speci?c 42 kD protein detected by the method
of the present invention in the photoaf?nity labeled
cerebral spinal ?uid from Alzheimer‘s disease patients is
mammalian glutamine synthetase (GS). -

identically with the 42kD photolabeled protein in the
cerebral spinal ?uid from Alzheimer’s disease patients.

1. Puri?ed GS (purchased from Sigma, puri?ed from
sheep brain) comigrated on SDS-PAGE identically
with the 42,000 M, protein in the cerebral spinal ?uid
from Alzheimer’s disease patients.

EXAMPLE 6-Development of an Immunoassay for the
Disease-Speci?c Alzheimer’s Disease Protein.
40
Levels of GS in brain homogenates from both nor
mal, control subjects and Alzheimer’s disease patients

2. Puri?ed GS and the 42 kD protein found in the

were assayed in terms of immunological response to a

cerebral spinal ?uid from Alzheimer’s disease patients

G5 antibody. GS was determined to be greatly elevated
in the samples from Alzheimer’s disease patients in com
binding ATP, 8-azido-ATP and 2-azido-ATP. That is, 45 parison to the control samples.
had the same approximate saturation and Kd values for

both proteins showed saturation of photoinsertion by
40-50 uM with half maximal photoinsertion occurring

By the presently claimed method, it will be possible
to isolate and purify the 42,000 M, protein for the spe
at about 10 uM with both 2-azido-ATP and 8-azido
ci?c production of both polyclonal and monoclonal
ATP. Also, ATP decreased the photolabeling of both
antibodies. Furthermore, since the 42,000 M, protein is
proteins, with either 8- or 2-azido-ATP, at nearly identi 50 glutamine synthetase with a speci?c substrate, it will be
cal concentrations of ATP. Therefore, both GS and the
possible to develop a biochemical assay for the presence
42 kD protein in the cerebral spinal ?uid from Alzhei
of this enzyme based on GS’s catalytic properties.
mer’s disease patients had the same nucleotide binding
A reliable diagnostic test for Alzheimer’s disease
properties.
requires the puri?cation and identi?cation of the spe
3. Photolabeling of puri?ed GS and the 42 kD protein 55 ci?c protein unique to Alzheimer’s diseased patients.
found in the cerebral spinal ?uid from Alzheimer’s dis
Production of antibodies to the speci?c protein will
ease patients exhibited the same kinetic properties upon
facilitate the development of immunoassay procedure.
addition of certain ligands known to affect the kinetics
EXAMPLE 7-Photolabeling of Cerebral Spinal Fluid
of GS with regards to binding of nucleotides. More
Samples from Amyotrophic Lateral Sclerosis and
speci?cally, the addition of 100 mM ammonium bicar 60
Alzheimer’s Disease Patients.
bonate enhanced the binding of [32P]2N3ATP, and
therefore the photolabeling of both the 42 kD cerebral
Cerebral spinal ?uid samples from 4 patients known
spinal ?uid protein and GS, by about 5-fold. Also, addi
to have amyotrophic lateral sclerosis (lane ALS) were

tion of 10 mM glutarate (a glutamate substrate analog)
slightly decreased the binding of [32P]2N3ATP, and
therefore slightly decreased the photolabeling of both
the 42 kD cerebral spinal ?uid protein and GS in the

compared with samples from patients with Alzheimer’s
disease (lanes AD). Each sample was processed,
photolabeled with [732P]8N3ATP or [732P]8N3GTP
and analyzed according to the procedures of Example

presence of excess ammonium bicarbonate.

1.

65
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The autoradiograph of an SDS-PAGE gel on which

d) subjecting the solubilized photoaf?nity-labeled

the proteins in the cerebral spinal ?uid samples were
screened, a speci?c protein of about 55,000 M, was

photolabeled with ['y32P]8N3GTP only in the cerebral
spinal ?uid samples from ALS patients. The 55,000 M,

protein to electrophoresis to separate the photoaf

?nity-labeled protein;

Vi

radiolabeled band was visible in each of the four sam

ples of [32P]8N3GTP photolabeled cerebral spinal ?uid
from ALS patients. Although the [32P]8N3GTP
photolabeled bands, ALS #l, appeared to be about
1/12 as intense as the corresponding protein bands, it
was nevertheless detectable.

e) detecting the presence of the separated photoaf?ni
ty~labeled protein; and
f) correlating the presence of the photoaf?nity
labeled protein to the presence of Alzheimer’s dis
ease.

3. The method for aiding in the diagnosis of Alzhei
mer’s disease according to claim 1, wherein the labeled

photoaf?nity labeling reagent is radioactively labeled.

By comparison, the [32P]8N3GTP photolabeled 55

4. The method for aiding in the diagnosis of Alzhei
mer’s disease according to claim 3, wherein the photoaf
?nity labeling reagent is activated by an ultraviolet light

kD protein was not observed in cerebral spinal ?uid
samples from Alzheimer’s disease patients or from sev
eral other non-ALS subjects. Moreover, no detectable

sufficient to effect photoactivation.
5. The method for aiding in the diagnosis of Alzhei
mer’s disease according to claim 2, wherein the solubi

photoinsertion into ‘the Alzheimer’s disease-speci?c 42
kD protein was found in the cerebral spinal ?uid sam

ples from ALS patients. Therefore, the present method

lized photoaf?nity-labeled protein is separated by gel

of photoaf?nity labeling with nucleotide af?nity probes

electrophoresis.

to identify unique disease-speci?c proteins in the pa

6. The method for aiding in the diagnosis of Alzhei
mer’s disease according to claim 3, wherein the radioac

tient’s cerebral spinal ?uid was shown to be effective in
the determination of the presence or development of
certain human neurological diseases or syndromes.

Although the present invention has been described 25
with reference to the presently preferred embodiment,

tively labeled photoaf?nity labeling reagent is [32F]
8-azidoadenosine-5'-triphosphate ([32P]8N3ATP) or

[32P]2-azidoadenosine-5’-triphosphate ([32P]2N3ATP).

it should be understood that the skilled artisan may

7. The method for aiding in the diagnosis of Alzhei
mer’s disease according to claim 3, wherein the radioac

make various modi?cations, substitutions, omissions,
and changes without departing from the spirit of the

tively labeled photoaf?nity labeling reagent is [321)]
S-azidoguanosine-5’-triphosphate ([32P]8N3GTP) or

invention. Accordingly, it is intended that the scope of 30
the present invention be limited only by the scope of the

[32P]2-azidoguanosine-5'-triphosphate ([32P]2N3GTP).

8. The method for aiding in the diagnosis of Alzhei
mer’s disease according to claim 2, in a patient af?icted
What is claimed is:
with Alzheimer’s disease, wherein the sample contains
l. A method for aiding in the diagnosis of Alzhei
no detected [32P]8N3cAMP photolabeled protein at an
mer’s disease in a mammal comprising:
35 apparent M, of about 68,000 daltons.
a) contacting a cerebrospinal ?uid sample which
9. A method for aiding in the diagnosis of amyo
contains a nucleotide binding protein having an
trophic lateral sclerosis in a mammal comprising:
apparent M, of about 42,000 daltons. wherein said
a) contacting a cerebrospinal ?uid sample which
protein is glutamine synthetase, with an effective
contains a nucleotide binding protein having an
apparent M, of about 55,000 daltons with an effec
amount of a labeled ATP- or GTP-analog photoaf 40

following claims. including equivalents thereof.

tive amount of labeled GTP~analog photoaf?nity
labeling reagent which speci?cally binds said nu
cleotide binding protein at the nucleotide binding
site to photoaf?nity label said nucleotide binding
protein;

?nity-labeling reagent which speci?cally binds said
nucleotide binding protein at the nucleotide bind
ing site to photoaf?nity label said nucleotide pro
tein:

b) fractionating said cerebrospinal ?uid sample to

b) fractionating said cerebrospinal ?uid sample to
separate the photoaf?nity-labeled nucleotide bind

separate the photoaf?nity-labeled nucleotide bind

ing protein;

ing protein;

c) detecting the presence of the separated photoaf?ni
ty-labeled nucleotide binding protein; and
d) correlating the presence of the photoaf?nity
labeled nucleotide binding protein to the presence

0) detecting the presence of the separated photoaf?ni
ty-labeled nucleotide binding protein; and
d) correlating the presence of the photoaf?nity
labeled nucleotide binding protein to the presence
of arnyotrophic lateral sclerosis.

of Alzheimer’s disease.
2. A method for aiding in the diagnosis of Alzhei
mer’s disease in a mammal comprising:

a) contacting a sample of cerebrospinal ?uid from a

55

mammal which contains a nucleotide binding pro

tein having an apparent Mrof about 42,000 daltons
with an effective amount of labeled ATP- or GTP

analog photoaf?nity-labeling reagent which specif
ically binds said nucleotide binding protein at the
nucleotide binding site to photoaf?nity label said

nucleotide binding protein;
b) precipitating the photoaf?nity-labeled protein
from the sample using an effective amount of a 65

precipitating agent;
c) solubilizing the precipitated photoaf?nity-labeled
protein;

10. The method for aiding in the diagnosis of amyo
trophic lateral sclerosis according to claim 9, wherein
the labeled photoaf?nity labeling reagent is radioac

tively labeled.

11. The method for aiding in the diagnosis of amyo
trophic lateral sclerosis according to claim 10, wherein
the photoaf?nity labeling reagent is activated by an
ultraviolet light suf?cient to effect photoactivation.
12. The method for aiding in the diagnosis of amyo
trophic lateral sclerosis according to claim 10, wherein

the radioactively labeled photoaf?nity labeling reagent

is
[32F]8-azidoguanosine-5’-triphosphate
([32P]8N3GTP).
13. A method for aiding in the diagnosis of Alzhei
mer’s disease in a mammal comprising:

23
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c) correlating the presence of said complexes with the

a) contacting a sample of cerebrospinal ?uid which

presence of Alzheimer's disease.
contains a nucleotide binding protein having an
14. The method of claim 13, wherein the antibody
apparent M, of about 42,000 daltons wherein said
speci?c for glutamine synthetase is labeled by binding
protein is glutamine synthetase, with a labeled anti 5 to a second labeled antibody.
15. The method of claim 14, wherein the glutamine
body speci?c for glutamine synthetase under con

synthetase-antibody complex formation is detected by

ditions that allow the formation of glutamine syn

enzyme linked immunosorbent assay, radioimmunoas
say, immunoradiometric assay, sandwich immunoradi

thetase-antibody complex formation;

ometric assay, ?uoroimmunoassay, chemiluminescent

b) detecting the presence of said glutamine synthe
tase-antibody complexes; and

assay, bioluminescent assay, or Western blot.
‘
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